BCL2A1 抗体
(BCL2-Related Protein A1 (BCL2A1))
This gene encodes a member of the BCL-2 protein family. The proteins of this family form hetero- or homodimers and act as anti- and pro-apoptotic regulators that are involved in a wide variety of cellular activities such as embryonic development, homeostasis and tumorigenesis. The protein encoded by this gene is able to reduce the release of pro-apoptotic cytochrome c from mitochondria and block caspase activation. This gene is a direct transcription target of NF-kappa B in response to inflammatory mediators, and is up-regulated by different extracellular signals, such as granulocyte-macrophage colony-stimulating factor (GM-CSF), CD40, phorbol ester and inflammatory cytokine TNF and IL-1, which suggests a cytoprotective function that is essential for lymphocyte activation as well as cell survival. Alternatively spliced transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Jul 2008].
| Catalog no. | 产品 | 适用 | 宿主 / 克隆类型 | 应用 | 价格和交货时间 |
|---|---|---|---|---|---|
| BCL2A1 抗体 (Ala1) | 人 | 兔 Polyclonal |
|
|
|
| BCL2A1 抗体 (AA 53-81) | 人 | 兔 Polyclonal |
|
|
|
| Recombinant BCL2A1 抗体 | 人 | 兔 Monoclonal |
|
|
|
| BCL2A1 抗体 (AA 1-175) | 人 | 兔 Polyclonal |
|
|
|
| Recombinant BCL2A1 抗体 | 人 | 兔 Monoclonal |
|
|
|
| BCL2A1 抗体 (C-Term) | 人, 大鼠, Pig, 猴 | 兔 Polyclonal |
|
|
|
| BCL2A1 抗体 (Internal Region) | 人, 小鼠 | 兔 Polyclonal |
|
|
|
| BCL2A1 抗体 (C-Term) | 人, 小鼠, 大鼠, Pig, 犬, Cow | 兔 Polyclonal |
|
|
|
| BCL2A1 抗体 (AA 31-130) | 人 | 小鼠 Polyclonal |
|
|
|
| BCL2A1 抗体 (Internal Region) | 人 | 山羊 Polyclonal |
|
|
|
| BCL2A1 抗体 (Middle Region) | 人 | 兔 Polyclonal |
|
|
|
| BCL2A1 抗体 (AA 30-65) (APC) | 人 | 兔 Polyclonal |
|
|
|
| BCL2A1 抗体 | 人, 小鼠 | 兔 Polyclonal |
|
|
|
| BCL2A1 抗体 | 人 | 小鼠 Monoclonal |
|
|
|
| BCL2A1 抗体 (AA 30-65) | 人 | 兔 Polyclonal |
|
|
|
| BCL2A1 抗体 (AA 30-65) (FITC) | 人 | 兔 Polyclonal |
|
|
|
| BCL2A1 抗体 (AA 30-65) (Biotin) | 人 | 兔 Polyclonal |
|
|
|
| BCL2A1 抗体 (AA 30-65) (PE) | 人 | 兔 Polyclonal |
|
|
|
| BCL2A1 抗体 (AA 30-65) (HRP) | 人 | 兔 Polyclonal |
|
|
|
| BCL2A1 抗体 (AA 1-16) | 人, 猴 | 兔 Polyclonal |
|
|
Primary Antibody
- WB (Western Blotting: 有验证图片)
- IHC (p) (Immunohistochemistry (Paraffin-embedded Sections): 有验证图片)
1 reference - 适用
- 人
- 宿主
- 兔
- 克隆形成能力
- Polyclonal
- 克隆
- RB1251
- 标记
- unconjugated
- 抗体亚型
- Ig Fraction
- 抗原表位
- AA 30-65, Ala1
Primary Antibody
- WB (Western Blotting: 有验证图片)
- FACS (Flow Cytometry: 有验证图片)
- IHC (p) (Immunohistochemistry (Paraffin-embedded Sections): 有验证图片)
- 适用
- 人
- 宿主
- 兔
- 克隆形成能力
- Polyclonal
- 克隆
- RB16877
- 标记
- unconjugated
- 抗体亚型
- Ig Fraction
- 抗原表位
- AA 53-81
Primary Antibody
- IHC (p) (Immunohistochemistry (Paraffin-embedded Sections): 有验证图片)
- WB (Western Blotting: 所列应用)
- IF (Immunofluorescence: 所列应用)
- ICC (Immunocytochemistry: 所列应用)
- IHC (fro) (Immunohistochemistry (Frozen Sections): 所列应用)
- 适用
- 人
- 宿主
- 兔
- 克隆形成能力
- Monoclonal
- 标记
- unconjugated
- 蛋白类型
- Recombinant Antibody
- 抗体亚型
- IgG
Primary Antibody
- IHC (Immunohistochemistry: 有验证图片)
- IF (Immunofluorescence: 有验证图片)
- ELISA (ELISA: 所列应用)
- 适用
- 人
- 宿主
- 兔
- 克隆形成能力
- Polyclonal
- 标记
- unconjugated
- 抗体亚型
- IgG
- 抗原表位
- AA 1-175
Primary Antibody
- WB (Western Blotting: 有验证图片)
- FACS (Flow Cytometry: 有验证图片)
- 适用
- 人
- 宿主
- 兔
- 克隆形成能力
- Monoclonal
- 克隆
- 23GB4820
- 标记
- unconjugated
- 蛋白类型
- Recombinant Antibody
- 抗体亚型
- IgG
Primary Antibody
- WB (Western Blotting: 有验证图片)
- IF (Immunofluorescence: 所列应用)
- ICC (Immunocytochemistry: 所列应用)
- 适用
- 人, 小鼠
- 宿主
- 兔
- 克隆形成能力
- Polyclonal
- 标记
- unconjugated
- 抗体亚型
- IgG
- 抗原表位
- Internal Region
Primary Antibody
- WB (Western Blotting: 有验证图片)
- 适用
- 人, 小鼠, 大鼠, Pig, 犬, Cow
- 宿主
- 兔
- 克隆形成能力
- Polyclonal
- 标记
- unconjugated
- 抗原表位
- C-Term
Primary Antibody
- WB (Western Blotting: 有验证图片)
- ELISA (ELISA: 所列应用)
- 适用
- 人
- 宿主
- 小鼠
- 克隆形成能力
- Polyclonal
- 标记
- unconjugated
- 抗原表位
- AA 31-130
Primary Antibody
- WB (Western Blotting: 有验证图片)
- ELISA (ELISA: 所列应用)
- 质量等级
- Verified
- 适用
- 人
- 宿主
- 山羊
- 克隆形成能力
- Polyclonal
- 标记
- unconjugated
- 抗体亚型
- IgG
- 抗原表位
- Internal Region
Primary Antibody
- WB (Western Blotting: 有验证图片)
- FACS (Flow Cytometry: 有验证图片)
- IHC (p) (Immunohistochemistry (Paraffin-embedded Sections): 有验证图片)
- EIA (Enzyme Immunoassay: 所列应用)
- 适用
- 人
- 宿主
- 兔
- 克隆形成能力
- Polyclonal
- 标记
- unconjugated
- 抗体亚型
- Ig Fraction
- 抗原表位
- AA 63-92, Middle Region
Primary Antibody
- WB (Western Blotting: 所列应用)
- ELISA (ELISA: 所列应用)
- IHC (Immunohistochemistry: 所列应用)
- 适用
- 人
- 宿主
- 兔
- 克隆形成能力
- Polyclonal
- 标记
- APC
- 抗体亚型
- IgG
- 抗原表位
- AA 30-65
Primary Antibody
- WB (Western Blotting: 所列应用)
- ELISA (ELISA: 所列应用)
- IHC (Immunohistochemistry: 所列应用)
- 适用
- 人
- 宿主
- 兔
- 克隆形成能力
- Polyclonal
- 标记
- unconjugated
- 抗体亚型
- IgG
- 抗原表位
- AA 30-65
Primary Antibody
- WB (Western Blotting: 所列应用)
- ELISA (ELISA: 所列应用)
- IHC (Immunohistochemistry: 所列应用)
- 适用
- 人
- 宿主
- 兔
- 克隆形成能力
- Polyclonal
- 标记
- FITC
- 抗体亚型
- IgG
- 抗原表位
- AA 30-65
Primary Antibody
- WB (Western Blotting: 所列应用)
- ELISA (ELISA: 所列应用)
- IHC (Immunohistochemistry: 所列应用)
- 适用
- 人
- 宿主
- 兔
- 克隆形成能力
- Polyclonal
- 标记
- Biotin
- 抗体亚型
- IgG
- 抗原表位
- AA 30-65
Primary Antibody
- WB (Western Blotting: 所列应用)
- ELISA (ELISA: 所列应用)
- IHC (Immunohistochemistry: 所列应用)
- 适用
- 人
- 宿主
- 兔
- 克隆形成能力
- Polyclonal
- 标记
- PE
- 抗体亚型
- IgG
- 抗原表位
- AA 30-65
Primary Antibody
- WB (Western Blotting: 所列应用)
- ELISA (ELISA: 所列应用)
- IHC (Immunohistochemistry: 所列应用)
- 适用
- 人
- 宿主
- 兔
- 克隆形成能力
- Polyclonal
- 标记
- HRP
- 抗体亚型
- IgG
- 抗原表位
- AA 30-65
Primary Antibody
- WB (Western Blotting: 所列应用)
- 适用
- 人, 猴
- 宿主
- 兔
- 克隆形成能力
- Polyclonal
- 标记
- unconjugated
- 抗体亚型
- IgG
- 抗原表位
- AA 1-16
Latest Publications for our BCL2A1 抗体
: "Dandelion root extract affects colorectal cancer proliferation and survival through the activation of multiple death signalling pathways." in: Oncotarget, Vol. 7, Issue 45, pp. 73080-73100, (2016) (PubMed).
: "Apoptotic body engulfment by hepatic stellate cells promotes their survival by the JAK/STAT and Akt/NF-kappaB-dependent pathways." in: Journal of hepatology, Vol. 51, Issue 1, pp. 139-48, (2009) (PubMed).
: "Association between genetic variants in VEGF, ERCC3 and occupational benzene haematotoxicity." in: Occupational and environmental medicine, Vol. 66, Issue 12, pp. 848-53, (2009) (PubMed).
: "Sirolimus-eluting versus bare-metal low-profile stent for renal artery treatment (GREAT Trial): angiographic follow-up after 6 months and clinical outcome up to 2 years." in: Journal of endovascular therapy : an official journal of the International Society of Endovascular Specialists, Vol. 14, Issue 4, pp. 460-8, (2007) (PubMed).
: "Weight loss reduces adipose tissue cathepsin S and its circulating levels in morbidly obese women." in: The Journal of clinical endocrinology and metabolism, Vol. 91, Issue 3, pp. 1042-7, (2006) (PubMed).
: "Gene expression changes and signaling events associated with the direct antimelanoma effect of IFN-gamma." in: Cancer research, Vol. 65, Issue 19, pp. 8869-77, (2005) (PubMed).
: "Up-regulation of Bfl-1/A1 via NF-kappaB activation in cisplatin-resistant human bladder cancer cell line." in: Cancer letters, Vol. 212, Issue 1, pp. 61-70, (2004) (PubMed).
: "Cell death in the third millennium." in: Cell death and differentiation, Vol. 7, Issue 1, pp. 2-7, (2000) (PubMed).
: "Structural basis of BFL-1 for its interaction with BAX and its anti-apoptotic action in mammalian and yeast cells." in: The Journal of biological chemistry, Vol. 275, Issue 15, pp. 11092-9, (2000) (PubMed).
: "A novel Bcl-2 related gene, Bfl-1, is overexpressed in stomach cancer and preferentially expressed in bone marrow." in: Oncogene, Vol. 11, Issue 9, pp. 1693-8, (1995) (PubMed).
: "Apoptotic body engulfment by hepatic stellate cells promotes their survival by the JAK/STAT and Akt/NF-kappaB-dependent pathways." in: Journal of hepatology, Vol. 51, Issue 1, pp. 139-48, (2009) (PubMed).
: "Association between genetic variants in VEGF, ERCC3 and occupational benzene haematotoxicity." in: Occupational and environmental medicine, Vol. 66, Issue 12, pp. 848-53, (2009) (PubMed).
: "Sirolimus-eluting versus bare-metal low-profile stent for renal artery treatment (GREAT Trial): angiographic follow-up after 6 months and clinical outcome up to 2 years." in: Journal of endovascular therapy : an official journal of the International Society of Endovascular Specialists, Vol. 14, Issue 4, pp. 460-8, (2007) (PubMed).
: "Weight loss reduces adipose tissue cathepsin S and its circulating levels in morbidly obese women." in: The Journal of clinical endocrinology and metabolism, Vol. 91, Issue 3, pp. 1042-7, (2006) (PubMed).
: "Gene expression changes and signaling events associated with the direct antimelanoma effect of IFN-gamma." in: Cancer research, Vol. 65, Issue 19, pp. 8869-77, (2005) (PubMed).
: "Up-regulation of Bfl-1/A1 via NF-kappaB activation in cisplatin-resistant human bladder cancer cell line." in: Cancer letters, Vol. 212, Issue 1, pp. 61-70, (2004) (PubMed).
: "Cell death in the third millennium." in: Cell death and differentiation, Vol. 7, Issue 1, pp. 2-7, (2000) (PubMed).
: "Structural basis of BFL-1 for its interaction with BAX and its anti-apoptotic action in mammalian and yeast cells." in: The Journal of biological chemistry, Vol. 275, Issue 15, pp. 11092-9, (2000) (PubMed).
: "A novel Bcl-2 related gene, Bfl-1, is overexpressed in stomach cancer and preferentially expressed in bone marrow." in: Oncogene, Vol. 11, Issue 9, pp. 1693-8, (1995) (PubMed).
Aliases for BCL2A1 抗体
BCL2 related protein A1 (BCL2A1) 抗体BCL2-related protein A1 (Bcl2a1) 抗体
BCL2-related protein A1 (BCL2A1) 抗体
ACC-1 抗体
ACC-2 抗体
BCL2A1 抗体
Bcl2a1d 抗体
BCL2L5 抗体
BFL1 抗体
GRS 抗体
HBPA1 抗体
您还需要查找其他产品吗？
You are here:
